THE developer of Russia's Sputnik V coronavirus vaccine said Friday (19) it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab.
The Russian Direct Investment Fund (RDIF), which backed the development of Sputnik V, said in a statement it had partnered with Stelis Biopharma 'to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine'.
Stelis Biopharma is expected to be able to start supplying the vaccine from the second half of the year.
RDIF, added that Stelis -- the biopharma unit of global pharmaceutical company Strides -- will work with the Russian wealth fund to provide supplies 'beyond the initial agreement'.
RDIF head Kirill Dmitriev said that the "significant vaccine volumes" produced with Stelis "will help widen access to the vaccine on a global scale".
RDIF said Friday that 52 countries have approved the use of Russia's Sputnik V, named after the Soviet-era satellite.
Moscow registered the jab in August before large-scale clinical trials, but leading medical journal The Lancet has since said it is safe and over 90 per cent effective.
Some Western countries have been wary of Sputnik over concerns the Kremlin would use it as a soft power tool to advance its interests.
AP Dhillon brings his signature style to Chanel’s front row
AP Dhillon making a statement at Paris Fashion Week—front row at Chanel 
AP Dhillon’s Paris Fashion Week debut is giving main character energy
Rap meets runway: AP Dhillon makes a bold statement at Paris Fashion Week
AP Dhillon cements his global influence at Chanel’s Paris show
AP Dhillon brings his Punjabi cool to Chanel’s front row—Paris wasn’t ready
Paris Fashion Week just got a Punjabi remix
Big Bear Lake, CaliforniaiStock
Las Vegas strip in Nevadaistock
Skyline, TampaiStock
Mayan ruins of Altun HaiStock
Cancun beachiStock
Old San Juan’s cobblestone streetsiStock
Old Port of Montreal iStock
Stricter regulations will be put in place to safeguard young consumersiStock